MENU
ZNTL
AS OF
Feb 3 closing price
Price
$2.82
Change
+$1.01 (+55.80%)
Capitalization
182.6M
28 days until earnings call
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2026 All rights reserved. Tickeron Inc.
ZNTL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Zentalis Pharmaceuticals (ZNTL) Ownership - Who owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more

#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
182.6M
P/E Ratio
N/A
Total Cash
280.7M
Projected Growth
N/A
Total Debt
36.71M
Revenue
26.87M
Risk (Beta)
1.75
Dividend Yield
N/A
Total Cash/Share
4.34
Total Debt/Equity
N/A
Revenue/Share
0.37 USD as % of share price

Fundamentals

ZNTL
Capitalization
183M
P/E Ratio
N/A
Risk (Beta)
1.75
Dividend Yield
N/A
Total Cash
281M
Total Cash/Share
4.34
Total Debt
36.7M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.37%
Revenue
26.9M
ROE
N/A
Book Value
253M
P/B Ratio
0.72
Cash Flow
N/A
Earnings
-2.08
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
72K
Current Ratio
7.76
Current Revenue Per Employee
241428.58
Dividends Per Share - Security
N/A
EBITDA
-152.83M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-38.39
Shares Held By Institutions
88.4M
Shares Outstanding - Current
64.8M
Total Liabilities
74.4M
Total Volume MTD
N/A
Value
1
Gain YTD
108.889
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
ZNTL
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ZNTL showed earnings on November 10, 2025. You can read more about the earnings report here.
View AI-Driven Trading for ZNTL
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com